BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…
Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces…
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBCPreliminary data from six-month evaluable…
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low…
May 2, 2024News release BioPorto A/S to Host First Quarter 2024 Earnings Webcast and Investor Meeting COPENHAGEN, DENMARK and BOSTON,…
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid…
Ovaterra's new formula is the first prenatal vitamin in the U.S. market to provide 100% of the essential nutrients a…
TORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" of the "Company"), a biopharmaceutical…
– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –…
FreeClimb 54 reperfusion system Route 92 Medical's new FreeClimb 54 reperfusion system, part of a growing portfolio of neurovascular devices…